# US 2014/0271462 A1 · Antigen binding constructs to cd8

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271462 A1
- Document ID: US20140271462A1
- Status: Published application
- Kind: A1
- Application number: 14/202,999
- Filed: 2014-03-10
- Published: 2014-09-18
- Earliest claimed: 2013-03-13
- Assignees: Imaginab, Inc.
- Applicants: Imaginab, Inc.
- Inventors: David T. Ho; Tove Olafsen; Giti Agahi; Christian P. Behrenbruch
- Web page: https://patentgrep.com/patent/US20140271462A1

## CPC

- C07K 16/2815: {against CD8}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/70517: CD8
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.

## Claims

### Claim 1

An antigen binding construct that comprises:
a HCDR1 of a HCDR1 of SEQ ID NO: 3 or 6;
a HCDR2 of HCDR1 of SEQ ID NO: 3 or 6;
a HCDR3 of HCDR1 of SEQ ID NO: 3 or 6;
a LCDR1 of LCDR1 of SEQ ID NO: 9;
a LCDR2 of LCDR1 of SEQ ID NO: 9; and
a LCDR3 of LCDR1 of SEQ ID NO: 9.

### Claim 2 (depends on 1)

The antigen binding construct of claim 1, wherein the antigen binding construct binds specifically to CD8.

### Claim 3 (depends on 1)

The antigen binding construct of claim 1, further comprising a detectable marker.

### Claim 4 (depends on 1)

The antigen binding construct of claim 1, further comprising a therapeutic agent.

### Claim 5 (depends on 1)

The antigen binding construct of claim 1, wherein the antigen binding construct is bispecific.

### Claim 6 (depends on 1)

The antigen binding construct of claim 1, wherein the antigen binding construct is a monovalent scFv.

### Claim 7

A humanized cys-diabody that binds to CD8, the humanized cys-diabody comprising a polypeptide that comprises:
a single-chain variable fragment (scFv) comprising a variable heavy (VH) domain linked to a variable light (VL) domain; and
a C-terminal cysteine.

### Claim 8 (depends on 7)

The humanized cys-diabody of claim 7, wherein the order of the variable domains, from N terminus to C terminus of the polypeptide is VL, VH.

### Claim 9 (depends on 7)

The humanized cys-diabody of claim 7, wherein the order of the variable domains, from N terminus to C terminus of the polypeptide is VH, VL.

### Claim 10 (depends on 7)

The humanized cys-diabody of claim 7, further comprising a detectable molecule.

### Claim 11 (depends on 7)

The humanized cys-diabody of claim 7, wherein the humanized cys-diabody comprises:
a HCDR1 of a HCDR1 of SEQ ID NO: 3 or 6;
a HCDR2 of HCDR1 of SEQ ID NO: 3 or 6;
a HCDR3 of HCDR1 of SEQ ID NO: 3 or 6;
a LCDR1 of LCDR1 of SEQ ID NO: 9;
a LCDR2 of LCDR1 of SEQ ID NO: 9; and
a LCDR3 of LCDR1 of SEQ ID NO: 9.

### Claim 12

A humanized minibody that binds to CD8, the humanized minibody comprising a polypeptide that comprises from N-terminus to C-terminus:
a single-chain variable fragment (scFv) that binds to CD8, the scFv comprising a variable heavy (VH) domain linked to a variable light (VL) domain;
a hinge-extension domain comprising a human IgG1 hinge region; and
a human IgG CH3 sequence.

### Claim 13 (depends on 12)

The humanized minibody of claim 12, further comprising a detectable marker.

### Claim 14 (depends on 12)

The humanized minibody of claim 12, wherein the humanized minibody comprises:
a HCDR1 of a HCDR1 of SEQ ID NO: 3 or 6;
a HCDR2 of HCDR1 of SEQ ID NO: 3 or 6;
a HCDR3 of HCDR1 of SEQ ID NO: 3 or 6;
a LCDR1 of LCDR1 of SEQ ID NO: 9;
a LCDR2 of LCDR1 of SEQ ID NO: 9; and
a LCDR3 of LCDR1 of SEQ ID NO: 9.

### Claim 15 (depends on 1)

A nucleic acid encoding an antibody of claim 1.

### Claim 16 (depends on 1)

A cell line producing an antibody of claim 1.

### Claim 17 (depends on 1)

A kit comprising:
an antigen binding construct of claim 1; and
a detectable marker.

### Claim 18 (depends on 1)

A method of detecting a presence or absence of a CD8, the method comprising:
applying the antigen binding construct of claim 1 to a sample; and
detecting a presence or an absence of the antigen binding construct, thereby detecting a presence of absence of a CD8.

### Claim 19 (depends on 18)

The method of claim 18, wherein the antigen binding construct is conjugated to a detectable marker.

### Claim 20 (depends on 18)

The method of claim 18, wherein applying the antigen binding construct comprises administering the antigen binding construct to a subject.

### Claim 21 (depends on 18)

The method of claim 18, wherein detecting binding or absence of binding of the antigen binding construct to CD8 comprises at least one of positron emission tomography or single-photon emission computed tomography.

### Claim 22 (depends on 18)

The method of claim 18, the method further comprising applying a secondary antigen binding construct to the sample, wherein the secondary antigen binding construct binds specifically to the antigen binding construct.

### Claim 23 (depends on 18)

The method of claim 18, wherein the antigen binding construct is incubated with the sample for no more than 20 hours.

### Claim 24 (depends on 18)

The method of claim 18, wherein the antigen binding construct is incubated with the sample for no more than 6 hours.

### Claim 25 (depends on 18)

The method of claim 18, wherein the antigen binding construct is administered to a host, and wherein a first quantity of antigen binding construct thereof is unbound to CD8, and a second quantity of antigen binding construct is bound to CD8, wherein at least about 80% of the first quantity of antigen binding construct is eliminated in no more than 12 hours.

### Claim 26 (depends on 1)

A method of targeting a therapeutic agent to a CD8, the method comprising administering to a subject an antigen binding construct of claim 1, wherein the antigen binding construct is conjugated to a therapeutic agent.
